

Elenco delle pubblicazioni

1. Tabellini G, Billi AM, Fala F, Cappellini A, Evangelisti C, Manzoli L, Cocco L, Martelli AM, Nuclear diacylglycerol kinase- θ is activated in response to nerve growth factor stimulation of PC12 cells. **Cell Signal** 2004; 16:1263-71. **IF= 3.388**
2. Tabellini G, Tazzari PL, Bortul R, Evangelisti C, Billi AM, Grafone T, Martinelli G, Baccarani M, Martelli AM, Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. **Br J Haematol** 2005; 130:716-25. **IF= 5.206**
3. Martelli AM, Fiume R, Faenza I, Tabellini G, Evangelisti C, Bortul R, Follo M, Fala F, Cocco L, Nuclear phosphoinositide specific phospholipase C (PI-PLC)- β 1: a central intermediary in nuclear lipid-dependent signal transduction. **Histol Histopathol** 2005; 20:1251-60. **IF= 1.777**
4. Martelli AM, Follo MY, Evangelisti C, Fala F, Fiume R, Billi AM, Cocco L, Nuclear inositol lipid metabolism: more than just second messenger generation? **J Cell Biochem** 2005; 96:285-92. **IF= 3.448**
5. Evangelisti C, Bortul R, Tabellini G, Papa V, Cocco L, Martelli AM, Nuclear expression of diacylglycerol kinases: possible involvement in DNA replication, **Eur J Histochem** 2006; 50:9-13. **IF= 2.425**
6. Martelli AM, Evangelisti C, Nyakern M, Manzoli FA, Nuclear protein kinase C. **Biochim Biophys Acta-Mol Cell Biol Lipids** 2006; 1761:542-51. **IF= 4.966**
7. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L, Phosphoinositide 3-kinase/Akt signalling pathway and its therapeutical implications for human acute myeloid leukemia. **Leukemia** 2006; 20:911-28. **IF= 9.944**
8. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Fala F, Cocco L, Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? **Cell Signal** 2006; 18:1101-7. **IF= 3.388**
9. Evangelisti C, Riccio M, Faenza I, Zini N, Hozumi Y, Goto K, Cocco L, Martelli AM, Subnuclear localization and differentiation-dependent increased expression of DGK- ζ in C2C12 mouse myoblasts. **J Cell Physiol** 2006; 209:370-8. **IF= 4.522**
10. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA, Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. **Biochim Biophys Acta-Mol Cell Res** 2007; 1773:1263-84. **IF= 4.739**

11. Martelli AM, Evangelisti C, Billi AM, Manzoli L, Papa V, Cocco L, Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells. **Acta Bio-Medica De L'ateneo Parmense**, 2007; 78:113-119.
12. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, Martelli AM, Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/AKT signal transduction network in human acute myelogenous leukemia blasts. **Leukemia** 2007; 21:427-38. **IF= 9.944**
13. Evangelisti C, Bortul R, Falà F, Tabellini G, Goto K, Martelli AM, Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks. **Histol Histopathol** 2007; 22:573-9. **IF= 1.777**
14. Martelli AM, Evangelisti C, Chiarini F, Blacock WL, Papa V, Falà F. The Phosphatidylinositol 3-kinase/Akt/Mammalian target of rapamycin signaling network as a new target for acute myelogenous leukaemia therapy. **Cancer Therapy** 2007.
15. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM, The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. **Leukemia** 2007; 21:886-96. **IF= 9.944**
16. Evangelisti C, Tazzari PL, Riccio M, Fiume R, Hozumi Y, Fala F, Goto K, Manzoli L, Cocco L, Martelli AM, Nuclear diacylglycerol kinase- ζ is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. **FASEB J** 2007; 21:3297-307. **IF= 5.391**
17. Martelli AM, Tabellini G, Bortul R, Nyakern M, Tazzari PL, Evangelisti C, Cocco L, The Phosphoinositide 3-Kinase (PI3K)/AKT signaling pathway as a therapeutic target for the treatment of human acute myeloid leukemia (AML). **Curr Signal Transd T** 2007; 2:246-56. **IF= 0.452**
18. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blacock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L, Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Beside. **Curr Med Chem** 2007; 14:2009-23. **IF= 3.894**
19. Papa V, Tazzari PL, Chiarini F, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM, Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukaemia cells. **Leukemia** 2008; 22:147-60. **IF= 9.944**

20. McCubrey JA, Abrams SL, Misaghian N, Wong EWT, Steelman LS, Basecke J, Troppmair J, Libra M, Nicoletti F, Molton S, McMahon M, **Evangelisti C**, Martelli AM, Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. **Leukemia** 2008; 22:2080-90. **IF= 9.944**
21. Tazzari PL, Tabellini G, Ricci F, Papa V, Chiarini F, **Evangelisti C**, Martinelli G, Contadini A, Cocco L, McCubrey JA, Martelli AM, Synergic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. **Cancer Res** 2008; 68:9394-403. **IF= 8.378**
22. **Evangelisti C**, Astolfi A, Gaboardi GC, Tazzari PL, Pession A, Goto K, Martelli AM, TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase- ζ -dependent cell cycle arrest. **Cell Signal** 2009; 21:801-9. **IF= 3.388**
23. Martelli AM, **Evangelisti C**, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA, Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. **Expert Opin Inv Drug** 2009; 18:1333-49. **IF= 4.031**
24. D'Emilio A, Biagiotti L, Burattini S, Battistelli M, Canonico B, **Evangelisti C**, Ferri P, Papa S, Martelli AM, Falcieri E, Morphological and biochemical patterns in skeletal muscle apoptosis. **Histol Histopathol** 2010; 25:21-32. **IF= 1.777**
25. **Evangelisti C**, Gaboardi GC, Billi AM, Ognibene A, Goto K, Tazzari PL, McCubrey J, Martelli AM, Identification of a functional nuclear export sequence in diacyl glycerol kinase- ζ . **Cell Cycle** 2010; 9:177-182. **IF= 3.259**
26. Martelli AM, Chiarini F, **Evangelisti C**, Grimaldi C, Ognibene A, Manzoli L, Billi AM, McCubrey JA, The Phosphatidylinositol 3-kinase/Akt/Mammalian target of rapamycin signaling network and the control of normal myelopoiesis. **Histol Histopathol** 2010; 25:669-680. **IF= 1.777**
27. Martelli AM, **Evangelisti C**, Chiarini F, McCubrey JA, The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. **Oncotarget** 2010; 1:89-103. **IF= 5.168**
28. Martelli AM, Papa V, Tazzari PL, Ricci F, **Evangelisti C**, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, McCubrey JA, Erucylphosphocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. **Leukemia** 2010; 24:687-98. **IF= 9.944**
29. Martelli AM, **Evangelisti C**, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, McCubrey JA, The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin

signaling network in normal myelopoiesis and leukemogenesis. **Biochim Biophys Acta-Mol Cell Res** 2010; 1803:991-1002. **IF= 4.739**

30. **Evangelisti C**, Ricci F, Tazzari PL, Chiarini F, Battistelli M, Falcieri E, Ognibene A, Pagliaro P, Cocco L, McCubrey JA, Martelli AM, Preclinical testing of the akt inhibitor triciribine in t-cell acute lymphoblastic leukemia. **J Cell Physiol** 2011; 226:822-31. **IF= 4.522**
31. Martelli AM, **Evangelisti C**, Chiarini F, Grimaldi C, McCubrey JA, The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. **Cancers (Basel)** 2010; 2;1576-1596. ISSN: 2072-6694. **IF= 6.162**
32. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, **Evangelisti C**, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, Pagliaro P, McCubrey JA, Martelli AM, Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. **Cancer Res** 2010; 70:8097-107. **IF= 8.378**
33. Martelli AM, **Evangelisti C**, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L, Targeting the phosphatidylinositol 3-Kinase/Akt/mammalian Target of Rapamycin signaling network in cancer stem cells. **Curr Med Chem** 2011; 18:2715-26 **IF= 3.894**
34. **Evangelisti C**, Ricci F, Tazzari PL, Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Martelli AM, Targeted Inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-Cell acute lymphoblastic leukemia. **Leukemia** 2011; 25;781-791. **IF= 9.944**
35. Martelli AM, **Evangelisti C**, Chappell WH, Abrams SL, Basecke J, Libra M, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA. Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. **Leukemia** 2011; 25;781-791. **IF= 9.944**
36. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, **Evangelisti C**, Martelli AM, Montalto G, Cervello M, McCubrey JA. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. **Aging** 2011; 3;192-222 **IF= 5.515**
37. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, **Evangelisti C**

- Cocco L, Martelli AM, McCubrey JA. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. **Oncotarget** 2011; 2;135-64. **IF= 5.168**
38. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. **Leukemia** 2011; 25;1080-94 **IF= 9.944**
39. McCubrey JA, Stelman LS, Abrams SL, Misaghian N, Chappell W, Bäsecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM. Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. **Curr Pharm Design** 2012; 18;1784-95 **IF= 2.412**
40. Martelli, AM, Ognibene, A, Buontempo, F, Fini, M, Bressanin, D, Goto, K, McCubrey, JA, Cocco, L, Evangelisti, C. Nuclear phosphoinositides and their roles in cell biology and disease. **Crit Rev Biochem Mol** 2011; 46;436-57 **IF= 6.069**
41. Okada M, Hozumi Y, Tanaka T, Suzuki Y, Yanagida M, Araki Y, Evangelisti C, Yagisawa H, Topham MK, Martelli AM, Goto K, DGK ζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. **Cell Signal** 2012; 24:1573-82. **IF= 3.388**
42. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA, Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. **Oncotarget** 2012; 3:371-94. **IF= 5.168**
43. Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, Manzoli L, Cappellini A, McCubrey JA, Targeting the liver kinase B1/Amp-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. **Expert Opin Inv Drug** 2012; 16:729-42. **IF= 4.031**
44. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM, Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. **Leukemia** 2012; 26:2336-2342. **IF= 9.944**

45. Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, Evangelisti C, The emerging multiple roles of nuclear Akt. **Biochim Biophys Acta-Mol Cell Res** 2012; 1823:2168-2178. **IF= 4.739**
46. Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM, Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. **Oncotarget** 2012; 3:811-23. **IF= 5.168**
47. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades. **Oncotarget** 2012; 3:954-87. **IF= 5.168**
48. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. **Oncotarget** 2012; 3:1608-111. **IF= 5.168**
49. McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN, Advances in targeting signal transduction pathways. **Oncotarget** 2012; 3:1505-21. **IF= 5.168**
50. Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Sparta A, McCubrey JA, Martelli AM, Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. **Expert Opin Ther Targets** 2013; 17:921-36. **IF= 4.621**
51. Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM, Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. **Leukemia**. 2014; 28:543-53 **IF= 9.944**

52. Martelli AM, Buontempo F, Evangelisti C GSK-3 β : a key regulator of breast cancer drug resistance. Cell Cycle. 2014; 13:697-8.
53. Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM, Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle. 2014; 13. **IF= 3.259**
54. Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D, Cappellini A, Orsini E, McCubrey JA, Martelli AM, Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia. Int J Oncol. 2014; 45:909-18. **IF= 3.571**
55. Evangelisti C, Evangelisti C, Teti G, Chiarini F, Falconi M, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Beak DJ, Bittman R, Pyne S, Pyne NJ, Martelli AM, Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget 2014; 5:7886-901. **IF= 5.168**
56. Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Neri LM, McCubrey JA, Martelli AM, Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. Biochim Biophys Acta-Mol Cell Res 2015; 1853:14-26. **IF= 4.739**
57. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM, Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci, 2015; 36:124-135. **IF= 11.523**
58. Evangelisti C, Bernasconi P, Cavalcante P, Cappelletti C, D'Apice MR, Sbraccia P, Novelli G, Baldini N, Lemma S, Avnet S, Prencipe S, Squarzoni S, Martelli AM, Lattanzi G, Modulation of TGF β 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget 2015; 6:7424-37. **IF= 5.168**
59. Lonetti A, Cappellini A, Spartà A, Chiarini F, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA, Martelli AM, PI3K pan-inhibition impairs more efficiently proliferation and survival of t-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget 2015; 6:10399-414 **IF= 5.168**
60. Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM, Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- κ B. Oncotarget 2016; 7:1323-40 **IF= 5.168**

61. Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM, Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. **Biochim Biophys Acta-Mol Cell Res** 2016; 1863:449-63 **IF= 4.739**
62. Evangelisti C, Cenni V, Lattanzi G, Potential therapeutic effects of the mTOR inhibitors for preventing ageing and progeria-related disorders. **Br J Clin Pharmacol** 2016; 82:1229-1244. **IF= 3.867**
63. Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, Chiarini F, Barata JT, Pyne S, Pyne NJ, Martelli AM, Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. **Leukemia** 2016; 30:2142-2151. **IF= 9.944**
64. Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, Zambonin L, Neri LM, Martelli AM, Chiarini F, Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. **J Hematol Oncol** 2016; 9:114. **IF= 8.731**
65. Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey J, Capitani S, Neri LM, PI3K isoform inhibition associated with anti BCR-ABL drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. **Oncotarget** 2017; 8:23213-27. **IF= 5.168**
66. Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata JT, Bertaina A, Locatelli F, Simioni C, Neri LM, Chiarini F, Lonetti A, Buontempo F, Orsini E, Pession A, Manzoli L, Martelli AM, Evangelisti C. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. **J Cell Physiol** 2018; 233:1796-1811 **IF= 4.522**
67. Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM. Therapeutic targeting of CK2 in acute and chronic leukemias. **Leukemia** 2018; 32:1-10. **IF= 9.944**
68. Bernasconi P, Carboni N, Ricci G, Siciliano G, Politano L, Maggi L, Mongini T, Vercelli L, Rodolico C, Biagini E, Boriani G, Ruggiero L, Santoro L, Schena E, Prencipe S, Evangelisti C, Pegoraro E, Morandi L, Columbaro M, Lanzuolo C, Sabatelli P, Cavalcante P, Cappelletti C, Bonne G, Muchir A, Lattanzi G. Elevated TGF β 2 serum levels in Emery-Dreifuss muscular dystrophy: implications for myocyte and tenocyte differentiation and fibrogenic processes. **Nucleus** 2018; 9:292-304. **IF= 2.157**

69. **Evangelisti C**, Chiarini F, McCubrey JA, Martelli AM. Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. **Int J Mol Sci** 2018; 19:1878 **IF= 4.183**
70. Chiarini F, **Evangelisti C**, Cenni V, Fazio A, Paganelli F, Martelli AM, Lattanzi G. The Cutting Edge: The Role of mTOR Signaling in Laminopathies. **Int J Mol Sci** 2019; 20:847 **IF= 4.183**
71. Chiarini F, **Evangelisti C**, Lattanzi G, McCubrey JA, Martelli AM. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. **Biochim Biophys Acta Mol Cell Res** 2019; 1866:1322-1337 **IF= 4.739**
72. **Evangelisti C**, Chiarini F, Paganelli F, Marmiroli S, Martelli AM. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. **Biochim Biophys Acta Mol Cell Res** 2019; 1867:118635. **IF= 4.739**
73. Evangelisti C, Chiarini F, Cappellini A, Paganelli F, Fini M, Santi S, Martelli AM, Neri LM, **Evangelisti C** Targeting Wnt/ β -catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. **J Cell Physiol** 2020; 235:413-5428 **IF= 4.522**
74. Martelli AM, Paganelli F, Chiarini F, **Evangelisti C**, McCubrey JA The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. **Cancers (Basel)** 2020; 12:333 **IF= 6.162**
75. Chiarini F, Paganelli F, Martelli AM, **Evangelisti C** The Role Played by Wnt/ β -Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. **Int J Mol Sci** 2020; 21:1098 **IF= 4.183**
76. **Evangelisti C**, Paganelli F, Giuntini G, Mattioli E, Cappellini A, Ramazzotti G, Faenza I, Maltarello MC, Martelli AM, Scotlandi K, Chiarini F, Lattanzi G Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. **Cells** 2020; 9:774. **IF= 5.656**